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Background: Femoral head osteonecrosis is frequently observed in patients treated with excessive corticosteroids.
The objective of the current study was to establish a rat model to investigate the disruption of immune response in
steroid-induced femoral head osteonecrosis via Toll-like receptor 4 (TLR4) signaling pathway.
Methods: Male SD rats were divided into the treatment group (group A) and the model group (group B)
consisting of 24 rats each, and were injected intramuscularly with 20 mg/kg methylprednisolone (MP) for 8 weeks,
once a week. The rats in group A were injected intravenously with 7.5 mg/kg TAK242 before each MP
administration. A control group (group N) consisted of 12 rats were received saline injection. All animals were
sacrificed 8, 10 and 12 weeks from the first MP injection, respectively. Histopathological analysis was performed and
the concentration of tartrate-resistant acid phosphatase (TRAP) in serum was tested. The signaling molecules
including TLR4, MyD88, NF-κB p65 and MCP-1 were detected by immunohistochemistry, quantitative real-time
PCR and Western blot.
Results: Femoral head osteonecrosis was observed in the model rats, and the concentration of TRAP and
positive staining of all signaling molecules increased significantly in group B compared with that in group A
and group N. Compare with the control group, the mRNA expressions and protein levels of all signaling
molecules were enhanced significantly in group B, but no significant in group A.
Conclusions: Corticosteroids can induce femoral head osteonecrosis by disturbing the immune response via
TLR4 signaling pathway. These findings suggest that the disruption of immune response play a role in the
pathogenesis of osteonecrosis.
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Steroid-induced osteonecrosis of femoral head often leads
to progressive collapse and followed by degenerative arth-
ritis. It is frequently caused by excessive corticosteroids
administration. The adverse effects of corticosteroids such
as obesity, hyperlipidemia, osteoporosis and Cushing syn-
drome have limited their clinical use, particularly at high
dose and for prolonged administration [1,2]. Recently, cor-
ticosteroid was considered a primary risk factor in
non-traumatic osteonecrosis. However, the underlying* Correspondence: wkzh1955@gmail.com
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reproduction in any medium, provided the orpathogenesis of steroid-induced femoral head osteo-
necrosis remains unclear [3-6], and effective prophy-
lactic treatment has not yet been identified. Recent
studies have implicated that the pathogenesis may be
multifactorial, which includes, osteoporosis, intravas-
cular fat emboli, vascular coagulation and abnormal
gene expression, maybe all of which interact and fi-
nally lead to the lesion [7-10].
To examine the pathogenesis of steroid-induced osteo-
necrosis, a disseminated intravascular coagulation shock
rabbit model has been developed in which osteonecrosis
is induced by administering lipopolysaccharide (LPS)
and methylprednisolone (MP) [11]. However, this model
shows metaphysic osteonecrosis and not the epiphysic. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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come these limitations, a rat model has been developed
in which osteonecrosis is induced by excessive MP
[12-14]. The rats genome is 90 percent similar to the hu-
man genome, and thus the pathological characteristics
of osteonecrosis in rats and human may be similar. In
addition, the femoral anteversion and neck-shaft angle
of rats are similar to that of humans, and the mechanical
property of the structures can be similar.
Toll-like receptor 4 (TLR4) is one of the most common
members in Toll-like receptors (TLRs) family, and it is
also the most thoroughly studied. As a pattern recognition
receptor, TLR4 has close relationship to autoimmune or
inflammatory diseases [15,16]. TLRs antagonists currently
under development are structural analogs of agonists
and probably bind to the receptor but fail to signal.
TAK-242, [ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl) sul-
famoyl] cyclohex-1-ene-1-carboxylate] (Figure 1), is a
TLR4 antagonist that is in a Phase III trial for the treat-
ment of inflammatory and autoimmune diseases. TAK242
acts as a selective inhibitor of signaling from the intracel-
lular domain of TLR4 [17,18], also inhibits activation
of nuclear factor-κB (NF-κB) and ligand-independent
NF-κB activation resulting from over-expression of
TLR4. MyD88 plays an important role in the MyD88-
dependent TLR4 signaling pathway, and can mediate
the signals transduct to the downstream. NF-κB, one
of the most important transcriptional signaling mole-
cules, participates in the downstream inflammatory
pathway and TLR4 signaling pathway, and its essential
role in osteoclastogenesis has been demonstrated gen-
etically. NF-κB can transduce signals by recruiting
adaptor molecules such as myeloid differentiation pri-
mary response gene 88 (MyD88) [19]. In addition, NF-
κB can activate monocyte chemotactic protein-1 (MCP-1)
that induces the proliferation of monocytes/macrophages,
which finally form osteoclasts.
Accordingly, the objectives of this study were to clarify
the pathogenesis of steroid-induced femoral head osteo-
necrosis and investigate the role of immune responseFigure 1 Structure of TLR antagonist: TAK-242 (Resatorvid).disorder in osteonecrosis via TLR4 signaling pathway




Male SD rats weighing 230-250 g (8-12 weeks old) were
obtained from the Animal Center of the Medical College
of Xi’an Jiaotong University (Xi’an, China). They were
specific pathogen free animals (SPFA) housed in clean,
temperature- and humidity-controlled SPFA chamber
with a room temperature of 22 ± 2°C, a relative humidity
of 50 ± 5%, unlimited food and water, and a 12 h light/
dark cycle.
Experimental protocols
All experiments abided by the guidelines of the Ministry
of Health, Culture, Science and Technology of China.
The experimental protocol was approved by the Animal
Ethics Committee of Xi’an Jiaotong University (Xi’an,
China). Forty-eight animals divided into the treatment
group (group A) and the model group (group B) consist-
ing of 24 rats each, all were injected intramuscularly
with 20 mg/kg MP (Pfizer Manufacturing, Belgium NV)
via bilateral gluteus maximus alternately for 8 weeks,
once a week. Based on a logistic regression model, la-
boratory variables before steroid injection were assessed
to determine whether they demonstrated any association
with the risk of ON. The rats in group A were injected
intravenously with 7.5 mg/kg TAK242 (Haoyuan Che-
mexpress Co., Ltd., Shanghai, China) before each MP
administration, also for 8 weeks, once a week. On the
basis of TAK242 dosage to human pharmacy clinical tri-
als (Phase III), and the dose conversion formula between
human and rat, the final dosage was calculated. The
control group (group N) consisted of 12 rats that were
fed and housed under identical conditions but were re-
ceived saline injection.
The rats in all groups were sacrificed by overdose of
anesthesia respectively at weeks 8, 10 and 12 from the
first MP injection, and the femoral heads were har-
vested. The left femoral heads of all rats were preserved
in -70°C cryogenic freezer immediately after sacrifice,
half of which were performed RNA isolation and the
others were performed protein isolation, respectively.
The right one was collected and furthered evenly divided
into two subgroups: one was fixed with 10% formalin
(0.1 M phosphate buffer, pH 7.4), and the other was
fixed with 2.5% glutaraldehyde solution in 4°C. Blood
was collected from the inferior vena cava into the anti-
coagulant tubes at the time of sacrifice and was centri-
fuged immediately. The supernatant serum was stored in
-70°C cryogenic freezer for Enzyme-Linked Immuno-
sorbent Assay (ELISA) analysis. The controlled animals
Tian et al. BMC Musculoskeletal Disorders 2014, 15:18 Page 3 of 12
http://www.biomedcentral.com/1471-2474/15/18were managed in the same way at weeks 8, 10 and 12,
respectively.
ELISA analysis
TRAP concentrations were determined using commer-
cial ELISA kits (R&D Systems, USA). Briefly, 50 μL of
standards, supernatant samples and controls were added
to each well of the coated microplate. Then, 50 μL spe-
cific biotin-conjugate antibodies were added to each
well, followed by 2 h incubation at 37°C. The liquid of
each well was discarded and the samples were incubated
for another 2 h at 20-22°C. The wells were then washed
three times, and 100 μL Streptavidin-HRP was added.
After further incubation for 1 h, the wells were washed
again and 100 μL substrate chromogen solutions were
added. After another incubation of 1 h and washing, 90
μL substrate solutions were added, followed by incuba-
tion at room temperature for 30 min. Finally, 50 μL of
stop solution was added. The absorbance of each well
was read within 30 min, spectrophotometrically at λ 450
nm. The mean O.D. value for each standard and sample
was calculated accordingly. All values were subtracted
by the mean value of the zero standard before result inter-
pretation. Finally, the curve equation of TRAP concentra-
tions was calculated, values were expressed as pg/ml
protein, and the standard curve was plotted according to
the amount in all the samples using GraphPad Prism 5.0
software (GraphPad Software, Inc., San Diego, California,
USA).
Histopathological staining
The bilateral femoral heads harvested from the animals
were immediately fixed with 10% formalin (0.1 M phos-
phate buffer, pH 7.4) at 4°C for 24 h, and then washed
with 0.2 M phosphate buffer (pH 7.4). Then, the speci-
mens were decalcified with 10% EDTA neutralized with
sodium sulphate buffer for about 4 weeks. After decalci-
fication, the tissues were embedded in paraffin and cut
in the coronal plane into 4 μm thick sections with a
microtome. Some of the sections were processed for
routine hematoxylin-eosin staining to assess the general
architecture and injury of the tissue. The stained sec-
tions were viewed at a magnification of 200 times and
photographed with eclipse 50i optical microscope im-
aging system (Nikon, Co. Ltd, Toyko, Japan), and the im-
ages were analyzed by Image-Pro-plus sofeware (Media
Cybernetics, Baltimore, MD).
Immunohistochemistry
The rest femoral head tissue sections obtained in the
above process were processed immunohistochemically
to detect the presence of TLR4, MyD88, NF-κB p65 and
MCP-1 using the avidin-biotin-peroxidase complex (ABC)
method. After permeabilized in phosphate-buffered saline(PBS) with 0.3% Triton-X 100 (pH 7.4) for 30 min and then
0.3% H2O2 for 1 h in order to block endogenous peroxid-
ase, the sections were incubated with primary mouse
anti-rat monoclonal antibodies (rabbit anti-rat, 1:200,
Santa Cruz Biotechnology, USA) against TLR4, MyD88,
NF-κB p65 and MCP-1 separately in a solution consisting
of 1% bovine serum albumin and 0.05% sodium azide in
0.1 M PBS for 24 h at 4°C. After three washings in PBS,
the specimens were exposed to biotinylated goat anti-
mouse IgG diluted 1:200 in PBS for 4 h at room
temperature. The peroxidase reaction was then developed
for 10 min in 0.05 M Tris buffer (pH 7.6) containing
0.02% 3, 3-diaminobenzidine tetrahydrochloride and
0.006% H2O2. The sections were photographed using
the eclipse 50i optical microscope imaging system, and
the images were analyzed by Image-Pro-plus sofeware.
Positive staining for the signaling molecules in sub-
chondral area of the femoral heads would be visible as
brown puncta and bundles distributed in the bone mar-
row, periosteum and bony trabeculae. The positive brown
staining provided in the protocol for each antibody was
used as positive control. Samples without primary anti-
bodies were used as negative controls. The intensities of
immunostaining for TLR4, MyD88, NF-κB p65 and MCP-
1 from group A, B and N were quantitatively analyzed. It
is important that all the sections were analyzed at the
same time for the quantitative study. The images obtained
were analyzed at a magnification of 200 times by quantita-
tive integrated optical density. The area of each analyzed
tissue was approximately the same. We evaluated the inte-
grated optical density, which referred to the sum of all the
pixel intensity or density values in a given region [20]. Ten
different regions in each tissue were randomly selected
and the numerical values obtained from the ten regions
were averaged to represent the specified marker in a given
tissue.
Quantitative real-time PCR (RT-qPCR) analysis
Total RNA was isolated with RNase-free DNase from
the femoral head by using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
protocol. The first strand of cDNA was synthesized from
0.5 μg of the total RNA by using 100 U of SuperScript™
II RnaseH-Reverse Transcriptase (Invitrogen) and 0.5 μg
of dT Primer (Invitrogen). PCR primers with the follow-
ing sequences were designed by Takara Biotechnology
(TaKaRa Biotechnology, Co. Ltd, Dalian, China): rat TLR4
forward primer, 5′-GGCATCATCTTCATTGTCCTTG-3′;
rat TLR4 reverse primer, 5′- AGCATTGTCCTCCCACT
CG-3′; rat MyD88 forward primer, 5′-AGAGTGGAGAG
CAGTGTC-3′; rat MyD88 reverse primer, 5′-GGCAG
TAGCAGATGAAGG-3′; rat NF-κB p65 forward primer,
5′-TGCAGGCTCCTGTGCGAGTG-3′; rat NF-κB p65 re-
verse primer, 5′-TCCGGTGGCGATCGTCTGTGT-3′; rat
Figure 2 The concentrations of TRAP by ELISA detection. In the
group B, the concentrations of TRAP were mounting steadily
during the experimental periods. Compared with the group N, the
concentrations increased significantly in the group B, but no
significant in the group A. There were significant difference
between group A and B. (P < 0.05: # vs. group N; ★ vs. group A;
P < 0.01: * vs. group N; Δvs. group A).
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TG-3′; rat MCP-1 reverse primer, 5′-CTGGTGATTCT
CTTGTAGTTCTCC-3′. And gene expression was nor-
malized by Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH): rat GAPDH forward primer, 5′-ATGGTGA
AGGTCGGTGTGAACG-3′; rat GAPDH reverse primer,
5′-CGCTCCTGGAAGATGGTGATGG-3′. PCR reactions
containing the fluorescent dye SYBR green were performed
in a DNA Engine Opticon RT-qPCR Detection System
(Bio-Rad, Hercules, California, USA). The amplification
was performed in a volume of 25 μL reaction mixture
containing 100 ng cDNA template with the PCR Mas-
ter Mix reagents kit (Cybrdi, Inc, Rockville, MD, USA).
The PCR program involved 45 cycles of 94°C for 10 s,
an annealing temperature (from 54°C to 64°C) for 30 s,
and 72°C for 30 s. The final results for each sample
were normalized relative to the relevant internal con-
trol value.
Western blot analysis
The protein levels of TLR4, MyD88, NF-κB p65 and
MCP-1 were detected by Western blotting. The speci-
mens were washed twice in ice-cold PBS and subse-
quently lysed in RIPA buffer, followed by grinding in
liquid nitrogen about 25 ~ 30 min. Supernatant solution
was extracted into the centrifuge tube, and insoluble ma-
terial was removed by microcentrifugation at 12000 r/min
for 10 min in 4°C. Protein of lysates were subsequently
dissolved in SDS sample buffer (62.5 mM Tris/HCl, pH
6.8, 2% w/v SDS, 10% glycerol, 50 mM dithiothreitol,
0.01% w/v bromophenol blue), electrophoresed on
SDS-PAGE with Tris-glycine running buffer, and elec-
trophoretically transferred onto polyvinylidene difluor-
ide membranes using a semi-dry apparatus (Bio-Rad,
Hercules, CA, USA). The membranes were blocked
with TBS/Tween20 (0.05 m Tris, 0.15 m NaCl, pH 7.6;
1% Tween20) containing 5% w/v non-fat dried milk for
1 h, and then were incubated in TBS/Tween20 with 5%
w/v non-fat dried milk supplemented with different
rabbit anti-rat monoclonal antibodies (rabbit anti-rat,
1:1000, Santa Cruz Biotechnology, USA) overnight at
4°C. After washed by TBS/Tween20 three times, the
membranes were incubated in the dark with the di-
luted (1:5000) secondary polyclonal antibody (goat anti-
rabbit conjugated with peroxidase) in TBS/Tween-20
containing 5% w/v non-fat dried milk at room temperature
for 2 h with gentle shaking. Horseradish peroxidase-
conjugated anti-β-actin (Santa Cruz Biotechnology, USA)
was used as an internal control. Positive antibody interac-
tions were visualized using an ECL-plus kit (Thermo Fisher
Scientific Inc, USA) with enhanced chemiluminescence sub-
strate for horseradish peroxidase. The luminescent signals
were detected and recorded by a CCD camera in the dark-
room, and transmitted to the controller unit. The data wasthen processed by the analysis equipment linked to the con-
troller unit.
Statistical analysis
All data were expressed as means ± SD. A Dunnett-t test
was used to analyze the significant differences of histo-
pathological staining, TRAP concentration, mRNA ex-
pressions and protein levels of the signaling molecules.
For multiple comparisons, the LSD t test and the
Student-Newman-Keuls (SNK) test were used to analyze
the statistical differences. A p-value less than 0.05 was
considered statistically significant.
Results
Concentration of TRAP in plasma
Standard curve of TRAP concentration was drawn ac-
cording to the OD values, and the curve equation was
calculated as y = 4.7216x-0.3994 (R2 = 0.9975). The ac-
tual concentrations were then calculated by the equation
and analyzed statistically (Figure 2). It was found that
the TRAP concentrations in group B were increasing
steadily and had significant difference compared with
that in group N during the experimental periods (p <
0.01), but the concentrations in group A had little in-
crease and had no obvious significance compared with
that in group N (p > 0.05). There were significant differ-
ences between group A and B (p < 0.05). These results
suggested that the glucocorticoids could make the osteo-
clasts activate and the TLR4 antagonists could reduce
the activation of osteoclasts.
Histopathological staining of osteonecrosis
Positive diagnosis of osteonecrosis was made on the
basis of the diffuse presence of empty lacunae or
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companied by surrounding bone marrow cell necrosis or
myelofibrosis as described in [21]. The mean rates of
osteonecrosis in group A and B were 20.8% (5 rats) and
45.8% (11 rats), and 7 rats were in bilateral femoral head
necrosis. The mean rate of empty lacunae in group A
and B were 10.21% and 36.97%. Figure 3 showed the
histopathology of the femoral head of groups A, B and
N after haematoxylin-eosin staining. In the group A, it
showed partial necrotic changes in bone trabeculae and
slight accumulation of degenerative or necrotic medul-
lary haematopoietic cells and fat cells in the surrounding
bone marrow. A few apparent empty lacunae were ob-
served. The increase of fibroblasts and osteoclasts were
not obvious. In the group B, the bone trabecular became
sparse and fracture, more empty lacunae were seen in it.
Haematopoietic cells and fat cells showed necrotic
changes, the fibroblasts and osteoclasts increased and
accumulated, and many activated osteoclasts were ob-
served and resorbing the necrotic bone trabeculae. The
performance of osteonecrosis became more and more
serious with time. There was no visible necrosis of bone
or bone marrow in the group N. These results showed
that the model of steroid-induced femoral head osteo-
necrosis had been successfully established.
Immunohistochemistry of the signaling molecules
The subchondral portion of the femoral head was the re-
gion of interest. Positive immunoreactivity in each group
was calculated and compared with the control group.
Immunostaining for TLR4, MyD88, NF-κB p65 and
MCP-1 increased intensively in group B, but slightly in
group A. Compared with the group N, quantitative ana-
lysis demonstrated a significant increase in immunola-
belling as a percentage of total bone volume for the
signaling molecules in group B (p < 0.05), but not in
group A. (p>0.05) (Figure 4). The expressions of TLR4
and MCP-1 in group B had significant differences com-
pared with that in group A at each time point (p < 0.05).
MyD88 and NF-κB p65 expressions in group B had sig-
nificant differences compared with that in group A at 12
weeks (p < 0.05). These results showed from both posi-
tive and negative aspects that the signaling molecules in-
volved in TLR4 signaling pathway increased and the
osteoclasts activated in the femoral head osteonecrosis.
TLR4 signaling pathway could play an important role in
the pathogenesis of osteonecrosis.
RT-qPCR of the signaling molecules
Figure 5 showed the mRNA expressions of the signal-
ing molecules in TLR4 signaling pathway. Compared
with the group N, the mRNA expressions of TLR4,
MyD88, and NF-κB p65 increased significantly in the
group B, but insignificantly in the group A. There was aremarkable difference in the increase of the MCP-1
mRNA expressions between group B and N (p < 0.05),
and no significant between groups A and N (p>0.05).
Between groups A and B, there were significant differ-
ences in the mRNA expressions of TLR4 and MCP-1 at
each time point and NF-κB p65 at 12 weeks (p < 0.05).
TLR4 signaling pathway could play an important role
in the activation of osteoclast and the pathogenesis of
osteonecrosis.
Protein level of the signaling molecules
Figure 6 presented the increase of protein levels of
TLR4, MyD88, NF-κB p65 and MCP-1 in the groups A
and B. The protein levels of the signaling molecules in
groups B were significantly increased compared with
that in group N (p < 0.05), whereas, there was no marked
difference in the cytokine levels between group A and
group N (p>0.05). Between group A and group B, the
protein levels of MyD88 and NF-κB p65 had significant
differences at each time point, and TLR4 expression at 8
and 10 weeks, MCP-1 expression at 10 and 12 weeks, all
had significant differences. These results showed from
both positive and negative aspects that TLR4 signaling
pathway could play an important role in the activation
of osteoclast and the pathogenesis of osteonecrosis.
Discussion
In the present study, we demonstrated that steroid-
induced femoral head osteonecrosis was generated in SD
rats by administering MP, and the osteoclast activity was
more increased in model groups than that in other
groups. The signaling molecules involved in TLR4 sig-
naling pathway were expressed highly and significantly
in model group compared with that in other groups.
Corticosteroids could induced the TLR4 signaling path-
way abnormally activated and disturbed the immune
response. As a result, the normal balance of bone me-
tabolism was disturbed, a large number of osteoclasts
were activated and proliferated, osteonecrosis of femoral
head was occurred. On the contrary, the osteonecrosis,
osteoclast activity and the signaling molecules involved
in TLR4 signaling pathway were showed no significant
differences in treatment groups compared with that in
control groups.
TLR4, a pattern recognition receptor mainly expressed
in monocyte/macrophage and dendritic cells, identifies
pathogenic microorganisms, recognizes pathogen associ-
ated molecular patterns, and takes part in the innate im-
munity and adaptive immune response [22,23]. It is also
expressed in bone cells, and its activation contributes to
TLR ligand-induced osteoclastogenesis and affects osteo-
clast differentiation [24,25]. It acts as a bridge connect-
ing immune responses and bone metabolism disorders
[26]. The signal transduction of TLR4 pathway is
A B N
Figure 3 (See legend on next page.)
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Figure 3 The observation of femoral head osteonecrosis by Hematoxylin-Eosin staining. In the group A, it showed partial necrotic
changes in bone trabeculae and slight accumulation of degenerative or necrotic medullary haematopoietic cells and fat cells in the surrounding
bone marrow. A few apparent empty lacunae were observed. The increase of fibroblasts and osteoclasts were not obvious. In the group B, the
bone trabecular became sparse and fracture, more empty lacunae were seen in it. Haematopoietic cells and fat cells showed necrotic changes,
the fibroblasts and osteoclasts increased and accumulated, and many activated osteoclasts were observed and resorbing the necrotic bone
trabeculae. The performance of osteonecrosis became more and more serious with time. There was no visible necrosis of bone or bone marrow
in the group N. (Magnification 200×, scale bar represents 100 μm for all figures, the green arrow stands for the empty lacunae, the red arrow
stands for the multinucleated giant cells or osteoclasts, and the blue arrow stands for the necrosis or fibrosis of bone marrow).
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NF-κB in the downstream of TLR4 pathway, and NF-κB
in turn induces co-stimulatory molecule expression to
activate osteoclasts [27]. NF-κB is an important tran-
scriptional signaling molecules regulating a variety of in-
flammatory and immune genic expressions [28,29]. It
has been confirmed that activated NF-κB exists in hu-
man endothelial cells, monocytes/macrophages and
smooth muscle cells [30]. NF-κB pathway is considered
the most significant signaling pathway to transduce the
intracellular signal to activate osteoclasts and stimulate
osteoclast precursor cells to mature [31]. MCP-1, a cyto-
kine existing in bone marrow, plays an important role in
promoting the activation of monocytes/macrophages
and causing the cells to gather in the region of bone
damage. The activation of monocytes/macrophages can
secrete a series of related signaling molecules to mediate
osteolysis, which is involved in the bone remodeling
process. We utilized the TLR4 antagonist: TAK242
(Resatorvid) as the intervention control group in this
study. TAK-242, a cyclohexene derivative, is a novel
small-molecule compound that selectively inhibits TLR4
signaling [32,33]. We reported previously that TLR4 is
indeed the target protein of TAK-242 and inhibits TLR4
signaling by disrupting the interactions of TLR4 with its
adaptor molecules. Although the site to which TAK-242
binds is located in the dimer interface of TLR4, TAK-
242 did not affect the dimerization of TLR4 in a protein
fragment complementation assay [34]. TAK-242 is a se-
lective inhibitor of signaling from the intracellular do-
main of TLR4 and represents a novel therapeutic
approach to the treatment of TLR4-mediated diseases.
In our study, we used a rat model of steroid-induced
femoral head osteonecrosis that had similar histopatho-
logical features with the steroid-treated patients to inves-
tigate the molecular mechanisms of osteonecrosis. From
week 8 to week 12, it was obvious that the histological
analysis identified necrotic bone cells surrounded by
necrotic bone marrow and necrotic regions with or
without being repaired near the epiphyses and subchon-
dral bone in the model groups, but slightly in the treat-
ment groups. However, it should be noted that the
structure of the femoral head in rat is different from that
in humans. The epiphyseal line of the femur is presentduring the whole adulthood of rats but not humans.
Osteonecrosis of femoral head may easily lead to a col-
lapse of joint in humans but not in rats [35,36]. In our
study, the necrosis of epiphysis in the femur was devel-
oped in the model groups.
Possibly, steroid-induced osteonecrosis arises due to
the activation of the TLR4 signaling pathway that sets
the destructive mechanisms in train. Observed in our
study, the concentrations of TRAP significantly in-
creased from week 8 to week 12, indicating that the os-
teoclastogenesis might be activated by corticosteroids.
MCP-1 also plays a very important role in activating and
aggregating the monocytes/macrophages [37]. Moreover,
steroid-induced osteonecrosis arose from the aberrant
immune response and the imbalance of bone metabol-
ism. The signaling molecules existed in TLR4 signaling
pathway increased significantly with time in the model
groups by the corticosteroids administration. These
changes might induce an abnormal immunological
microenvironment, disturb the balance of immune sys-
tem and provoke the proliferation of osteoclasts via
TLR4 signaling pathway. However, the longest observa-
tion time in the present experiment was 12 weeks. A
prolonged observation period may better elucidate the
pathogenesis of osteonecrosis.
Generally, a rigid skeletal bone is considered as involv-
ing a dynamic process of formation and resorption of
the bone matrix, carried out by osteoblasts and osteo-
clasts, respectively. The process is kept in balance to
maintain calcium metabolism and skeletal integrity. Os-
teoclasts can absorb the bone tissues, make the bone re-
sorption exceeds the osteogenesis, destroy the structure
of trabecular bone and lead to multiple microfractures.
Aaron [38] suggested that the remodeling cycle occured
simultaneously when damages appear in the adjacent
areas of bone, but the resorption is predominant, caus-
ing further destroy of the subchondral bone and ultim-
ately leading to progressive collapse of the trabeculae
and finally lead to progressive joint damage [39]. The
immune system is spawned in the bone marrow reser-
voir, and bone also can respond to the certain physio-
logical and immunological demands via releasing
cytokines and other signaling molecules into the blood-
stream. Therefore, the mechanism of osteonecrosis is
Figure 4 (See legend on next page.)
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Figure 4 The positive staining of the signaling molecules in the three groups by immunohistochemistry. Quantitative analysis
demonstrated significant increase in immunolabeling as a percentage of total bone volume for the signaling molecules in the group B.
Compared with the group N, the immunostaining for the signaling molecules in the group B increased significantly, but no significant in the
group A. The expressions of TLR4 and MCP-1 in group B had significant differences compared with that in group A at each time point. MyD88
and NF-κB p65 expressions in group B had significant differences compared with that in group A at 12 weeks. (IOD: integrated optical density,
P < 0.05: # vs. group N; ★ vs. group A; P < 0.01: * vs. group N; Δ vs. group A).
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involve an abnormality in bidirectional regulation. Ex-
cessive corticosteroids administration could disturb the
normal immune response and lead to pathological bone
resorption. Vink [40] have found that the TLR4 signaling
pathway played an important regulated role in the prolif-
eration and differentiation of osteoclasts. Recent studies
have elucidated the unanticipated connections between
immune system and skeletal system, which have led to
the development of a new known field called osteoim-
munology, an interdisciplinary research focused on the
molecular understanding of the interplay of the skeletal
and immune systems [41]. Thus, the immune cells haveFigure 5 The mRNA expressions of the signaling molecules in the rats
p65 and MCP-1 increased with time in the group B. Compared with the gr
significant in the group A. Between groups A and B, there were signif
each time point and NF-κB p65 at 12 weeks. (P < 0.05: # vs. group N; ★been implicated in the orthopaedic diseases [42], and the
bone remodeling is under the control of several local
and systemic factors, including the immune system.
Conclusions
We have identified that the disorder of immune re-
sponse via TLR4 signaling pathway plays a role in the
pathogenesis of steroid-induced femoral head osteo-
necrosis. The inhibition of osteoclastogenesis may play a
role in reducing the excessive bone loss caused by the
disorder of immune response. Therapeutic strategies,
such as immunomodulatory biologic drugs specifically
targeted at immune cells or signaling molecules, mightfemoral heads of all groups. The expressions of TLR4, MyD88, NF-κB
oup N, there was a significant difference in the group B, but no
icant differences in the mRNA expressions of TLR4 and MCP-1 at
vs. group A; P < 0.01: * vs. group N; Δ vs. group A).
Figure 6 The protein levels of the signaling molecules in the rats femoral heads of all groups. Compared with the group N, there were
remarkable increases in the protein levels of TLR4, MyD88, NF-κB p65 and MCP-1 in the group B, and slight increases in the group A. The MCP-1
levels in groups B showed most significantly, there was no marked difference between group A and group N. Between group A and group B,
the protein levels of MyD88 and NF-κB p65 had significant differences at each time point, and TLR4 expression at 8 and 10 weeks, MCP-1 expres-
sion at 10 and 12 weeks, all had significant differences. (P < 0.05: # vs. group N; ★ vs. group A; P < 0.01: * vs. group N; Δ vs. group A).
Tian et al. BMC Musculoskeletal Disorders 2014, 15:18 Page 10 of 12
http://www.biomedcentral.com/1471-2474/15/18
Tian et al. BMC Musculoskeletal Disorders 2014, 15:18 Page 11 of 12
http://www.biomedcentral.com/1471-2474/15/18be a beneficial feature of its clinical use for bone
erosion-associated joint diseases.
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